Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Randomized, Placebo and Alprazolam-controlled Three-period Crossover Incomplete Block Design Study to Compare Putative Anxiolytic-like fRMI Activity of GW876008 and GSK561679 After Single-dose Administration in Subjects With Social Anxiety Disorder (SAD)

NCT00555139 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00555139
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00555139 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Randomized, Placebo and Alprazolam-controlled Three-period Crossover Incomplete Block Design Study to Compare Putative Anxiolytic-like fRMI Activity of GW876008 and GSK561679 After Single-dose Administration in Subjects With Social Anxiety Disorder (SAD)
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
March 27, 2007
Completion date
January 10, 2008
Enrollment
35 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

social phobia